이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

GeneOne Life Science 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Young-Keun Park

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	9.0%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

Is GeneOne Life Science (KRX:011000) Using Debt In A Risky Way?

Mar 20

GeneOne Life Science (KRX:011000) Has Rewarded Shareholders With An Exceptional 855% Total Return On Their Investment

Jan 10

CEO

Young-Keun Park (60 yo)

no data

테뉴어

Mr. Young-Keun Park, J.D., MBA, is the Chief Executive Officer of at GeneOne Life Science, Inc. and served as its director and President. He serves as Director at GeneOne Life Science, Inc. Mr. Park is the...

GeneOne Life Science 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Less than half of directors are independent

GeneOne Life Science, Inc., Annual General Meeting, Mar 31, 2021

Recent updates

New minor risk - Shareholder dilution

GeneOne Life Science, Inc. has withdrawn its Follow-on Equity Offering in the amount of KRW 66.66 billion.

Full year 2023 earnings released: ₩1,000 loss per share (vs ₩492 loss in FY 2022)

GeneOne Life Science, Inc. announced that it expects to receive KRW 3.6000014 billion in funding

New major risk - Financial position

New minor risk - Share price stability

Less than half of directors are independent

Less than half of directors are independent

GeneOne Life Science, Inc. announced that it expects to receive KRW 11.7 billion in funding

Third quarter 2021 earnings released: ₩122 loss per share (vs ₩58.00 loss in 3Q 2020)

Is GeneOne Life Science (KRX:011000) Using Debt In A Risky Way?

Full year 2020 earnings released: ₩397 loss per share (vs ₩356 loss in FY 2019)

GeneOne Life Science, Inc., Annual General Meeting, Mar 31, 2021

New 90-day low: ₩13,800

New 90-day low: ₩16,550

New 90-day low: ₩19,400

GeneOne Life Science (KRX:011000) Has Rewarded Shareholders With An Exceptional 855% Total Return On Their Investment

New 90-day low: ₩24,200

GeneOne Life Science, Inc. announced that it expects to receive KRW 24 billion in funding from a group of investors

VGX Pharmaceuticals, Inc. Terminates CELLECTRA Device License Agreement with GeneOne

New 90-day high: ₩39,000

New 90-day low - ₩8,430

GeneOne Life Science, Inc. has completed a Follow-on Equity Offering in the amount of KRW 76.475 billion.

CEO

테뉴어